Please upgrade your browser.
"We could eventually predict for individual patients before we treat them what the likelihood is that they would respond," said Dr. Ewend.
A trial-in-progress update on AGS-003 from the 2014 ASCO GU meeting in San Francisco.
Argos Therapeutics To Present Progress Update On Adapt Phase 3 Trial With AGS-003 At 2014 Genitourinary Cancers Symposium
Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that the company will present a trial-in-progress update on the company's ongoing pivotal phase 3 clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC).
This randomized controlled trial examined the quality-of-life benefits of an expressive writing (EW) intervention for patients with renal cell carcinoma (RCC) and identified a potential underlying mechanism of intervention efficacy.
Vote in the Uplifting Athletes Competition Today
The response of a patient with metastatic brain tumors to treatment with stereotactic radiosurgery in the first six-to-twelve weeks can indicate whether follow-up treatments and monitoring are necessary, according to research conducted at the University of North Carolina.
The mTOR (mammalian target of rapamycin) inhibitor, everolimus, affects tumor growth by targeting cellular metabolic proliferation pathways and delays renal cell carcinoma (RCC) progression.
Complication rates of open partial nephrectomies (OPN) and minimally invasive partial nephrectomies (MIPN) have largely been reported by single and multi-institutional tertiary care centers.
One in three patients with kidney cancer eligible to receive one of two new medicines – sunitinib or pazopanib – did not get them due to the area they live in.
|Powered by NeonCRM|